youtube
Ed Ingham of Haggerston BioHealth shares his 6-tab due diligence framework for researching biotech stocks using Seeking Alpha Premium—covering everything from CRISPR and FDA risk to cash burn, filings, and earnings data.
In this video, you’ll learn how to research biotech stocks using a structured, professional-grade process. Ed walks through his “6-tab method,” showing how to analyze company fundamentals, evaluate risk, and stay on top of critical developments that impact biotech investing.
He breaks down how to:
• Use earnings call transcripts and conference insights to understand management strategy
• Analyze earnings press releases for pipeline updates and key financial metrics
• Review SEC filings (10-K, 10-Q) to uncover risks and competitive dynamics
• Monitor recent news, FDA decisions, and analyst updates
• Evaluate financials, including cash burn, runway, and funding needs
• Revisit past analysis to validate or challenge your investment thesis
This approach is especially critical for biotech investing, where factors like clinical trials, regulatory approvals, and capital requirements can significantly impact stock performance.
Whether you're new to biotech stocks or looking to strengthen your due diligence process, this video provides a clear, repeatable framework for making more informed investment decisions.
Follow Edmund Ingham on Seeking Alpha! -
For more insights from Ed Ingham, join Haggerston BioHealth today! -
Get Started With Seeking Alpha Premium N
|
